1 November 2019


TEIPP-targeting immunotherapy project funded by Oncode Institute

Oncode clinical Proof of concept Programme will fund the “TEIPP-targeting immunotherapy” project from Sjoerd van der Burg

Elize Brolsma

Oncode created a clinical Proof-of-Concept fund (cPoC) to support the clinical translation of Oncode’s fundamental research. Together with support from our OEDES team, Clinical Advisory board and Valorization team, Oncode Investigators and their co-workers are developing their research into pre-clinical and clinical projects.

We are pleased to announce that the 7th grant with the cPoC programme has been awarded to Oncode Investigator Sjoerd van der Burg (LUMC), his colleague Thorbald van Hall (LUMC) and pulmonary oncologist Joachim Aerts (Erasmus MC). Together they will develop TEIPP (T-cell epitopes associated with impaired peptide processing)-targeting immunotherapy, a potential anticancer vaccine.

Immunotherapy is an important part of the treatment of some cancers and help the immune system by recognizing and killing cancer cells. Unfortunately, tumors have developed several escape mechanisms, including losing the presentation of T-cell epitopes on cancer cells leading to failure of tumor-reactive T-cells to recognize and kill these tumor cells. Sjoerd and colleagues have developed a vaccine for cancer patients, with the goal to specifically stimulate the immune system to make the cancer cells available again for recognition by the immune cells. After years of fundamental research by them, this project will now be continued in a clinical setting for non-small cell lung cancer.

Other News

Founding Principles Card@2X
New vacancies at Oncode Partner Institutes
Are you planning on the next steps in your scientific career? Check out the latest vacancies at the labs of Oncode Investigators.
About Card
Researchers explain the added value of Oncode Institute
At this year's Oncode-CGC Annual conference, we took the time to speak with some of our Oncode Investigators. In this video, they explain the value that Oncode adds to their research, collaboration opportinuties and valorization success.
Oncode Institute invests 4 million euros in new technology for cancer research in the Netherlands
Oncode Institute invests 4 million euros in unique, state-of-the-art technology for cancer research. Five projects have been awarded within the Infrastructure & Technologies Programme. These technologies will not only become available for the twelve institutes that are affiliated with Oncode Institute but will also be made available to the wider research community in the Netherlands.